Ingrid Marchal-Gérez

EMEA Senior Cell Therapy Commercial Operations Leader • Janssen

At Johnson & Johnson, Ingrid Marchal-Gerez is responsible for overseeing the EMEA cell therapy commercial operations. Over the past four years, she has been instrumental in establishing new commercial capabilities for cell therapy, which involve introducing fresh roles, processes, and platforms. Ingrid has worked closely with the supply chain to ensure effective collaboration. In 2013, she joined J&J, initially focusing on digital health and healthcare solutions. In these roles, she led the development and implementation of innovative solutions to empower and assist patients across various disease areas, including oncology, psychiatry, metabolic diseases, and surgery. Before her time at J&J, Ingrid spent ten years as an entrepreneur and business developer in the field of industrial biotechnology. Her efforts supported industries in enhancing and innovating biological processes. Ingrid holds a PhD in biochemistry from the University of Lille, France, and an MBA from London Business School. Outside of work, she is a dedicated runner and a mother of two.

Also speaking

Stefanie Urlinger

Chief Scientific Officer • Cimeio Therapeutics

Dirk Schmitt

Sr. Medical Director Medical Affairs • Taysha Gene Therapies

Ben Doak

Head of Innovative Treatments • NHS England

Event Info


Event Brochure

Take a look at the 2023 Event Brochure for Advanced Therapies Europe.

Download the 2023 Speaker List

Download the 2023 Speaker List for Advanced Therapies Europe here.